Cargando…
Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
For advanced non-squamous non-small cell lung cancer (NSCLC), although platinum/pemetrexed is known to result in a longer survival compared with other regimens, the outcome in the adjuvant setting is still unknown. In this study, the difference of the disease-free survival (DFS) between lung adenoca...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431114/ https://www.ncbi.nlm.nih.gov/pubmed/28469143 http://dx.doi.org/10.1038/s41598-017-01347-6 |
_version_ | 1783236368224223232 |
---|---|
author | Zhai, Xiaoyu Zheng, Qiwen Yang, Lu Zhu, Yixiang Li, Junling Liu, Yutao Wang, Ziping |
author_facet | Zhai, Xiaoyu Zheng, Qiwen Yang, Lu Zhu, Yixiang Li, Junling Liu, Yutao Wang, Ziping |
author_sort | Zhai, Xiaoyu |
collection | PubMed |
description | For advanced non-squamous non-small cell lung cancer (NSCLC), although platinum/pemetrexed is known to result in a longer survival compared with other regimens, the outcome in the adjuvant setting is still unknown. In this study, the difference of the disease-free survival (DFS) between lung adenocarcinoma patients treated with platinum/pemetrexed and with other platinum-based doublets was concerned. A total of 389 radically resected lung adenocarcinoma patients received adjuvant chemotherapy with platinum/pemetrexed chemotherapy (Group A, n = 143) or other third generation platinum-based regimens (Group B, n = 246) were analyzed in terms of DFS. Propensity score matching (PSM) allowed generation of best matched pairs for the two categories. DFS was proved to be considerably better in pemetrexed doublets group (P = 0.0079); and platinum/pemetrexed was found to be associated with lower rates of several hematological and non-hematological adverse events (AEs), when compared with gemcitabine containing chemotherapy (leukopenia: RR 0.514, p = 0.001; neutropenia: RR 0.688, p = 0.002), or taxanes-doublets treatment (leukopenia: RR 0.685, p = 0.019; neutropenia: RR 0.805, p = 0.032). For patients with radically resected pulmonary adenocarcinoma, adjuvant chemotherapy with platinum/pemetrexed results in a better DFS and a less clinical toxicity in comparison with non-pemetrexed based doublets. |
format | Online Article Text |
id | pubmed-5431114 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-54311142017-05-16 Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma Zhai, Xiaoyu Zheng, Qiwen Yang, Lu Zhu, Yixiang Li, Junling Liu, Yutao Wang, Ziping Sci Rep Article For advanced non-squamous non-small cell lung cancer (NSCLC), although platinum/pemetrexed is known to result in a longer survival compared with other regimens, the outcome in the adjuvant setting is still unknown. In this study, the difference of the disease-free survival (DFS) between lung adenocarcinoma patients treated with platinum/pemetrexed and with other platinum-based doublets was concerned. A total of 389 radically resected lung adenocarcinoma patients received adjuvant chemotherapy with platinum/pemetrexed chemotherapy (Group A, n = 143) or other third generation platinum-based regimens (Group B, n = 246) were analyzed in terms of DFS. Propensity score matching (PSM) allowed generation of best matched pairs for the two categories. DFS was proved to be considerably better in pemetrexed doublets group (P = 0.0079); and platinum/pemetrexed was found to be associated with lower rates of several hematological and non-hematological adverse events (AEs), when compared with gemcitabine containing chemotherapy (leukopenia: RR 0.514, p = 0.001; neutropenia: RR 0.688, p = 0.002), or taxanes-doublets treatment (leukopenia: RR 0.685, p = 0.019; neutropenia: RR 0.805, p = 0.032). For patients with radically resected pulmonary adenocarcinoma, adjuvant chemotherapy with platinum/pemetrexed results in a better DFS and a less clinical toxicity in comparison with non-pemetrexed based doublets. Nature Publishing Group UK 2017-05-03 /pmc/articles/PMC5431114/ /pubmed/28469143 http://dx.doi.org/10.1038/s41598-017-01347-6 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Zhai, Xiaoyu Zheng, Qiwen Yang, Lu Zhu, Yixiang Li, Junling Liu, Yutao Wang, Ziping Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma |
title | Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma |
title_full | Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma |
title_fullStr | Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma |
title_full_unstemmed | Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma |
title_short | Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma |
title_sort | impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431114/ https://www.ncbi.nlm.nih.gov/pubmed/28469143 http://dx.doi.org/10.1038/s41598-017-01347-6 |
work_keys_str_mv | AT zhaixiaoyu impactofplatinumpemetrexedcombinationversusotherplatinumbasedregimensonadjuvantchemotherapyinresectedlungadenocarcinoma AT zhengqiwen impactofplatinumpemetrexedcombinationversusotherplatinumbasedregimensonadjuvantchemotherapyinresectedlungadenocarcinoma AT yanglu impactofplatinumpemetrexedcombinationversusotherplatinumbasedregimensonadjuvantchemotherapyinresectedlungadenocarcinoma AT zhuyixiang impactofplatinumpemetrexedcombinationversusotherplatinumbasedregimensonadjuvantchemotherapyinresectedlungadenocarcinoma AT lijunling impactofplatinumpemetrexedcombinationversusotherplatinumbasedregimensonadjuvantchemotherapyinresectedlungadenocarcinoma AT liuyutao impactofplatinumpemetrexedcombinationversusotherplatinumbasedregimensonadjuvantchemotherapyinresectedlungadenocarcinoma AT wangziping impactofplatinumpemetrexedcombinationversusotherplatinumbasedregimensonadjuvantchemotherapyinresectedlungadenocarcinoma |